Riskpilot← Back to searchSign inGet full accessA3P Biomedical AB (publ)
ABActiveOrg 5592529100Kungsgatan 24Activities of head offices · NACE 7010Est. 202032 employees
Revenue 2024
SEK 3M
-14% vs 2023
EBITDA margin
-2554.3%
+8% vs 2023
Equity ratio
93.1%
Financial strength
Net profit 2024
SEK -70,7M
+14% vs 2023
| Revenue | SEK 3M | -14% |
| EBITDA | SEK -75,8M | +8% |
| Net profit | SEK -70,7M | +14% |
| Total assets | SEK 253,2M | -23% |
| Equity | SEK 235,7M | -23% |
| Employees | 32 | — |
Legal name
A3P Biomedical AB (publ)
Org number
5592529100
Legal form
Aktiebolag
NACE code
7010 · Activities of head offices
Founded
21 april 2020
Share capital
SEK 759 000
Employees
32 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Firman tecknas av Steinberg, Jan Martin i förening med O'Connell, Christopher James Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget har till föremål för sin verksamhet att, direkt eller indirekt, utveckla, tillverka och marknadsföra system för förbättrad precision av prostatacancerdiagnostik och prostatacancerbehandling och därmed förenlig verksamhet.
Address
Kungsgatan 24
Email
info@a3p.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 18 950 | 4 621 | 3 436 | 2 968 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −4 651 | −23 912 | −59 487 | −82 693 | −75 812 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | −4 651 | −23 912 | −59 487 | −82 693 | −75 812 |
| Net financials | — | 614 | 2 590 | 9 447 | 8 632 |
| Profit before tax | −4 651 | −41 798 | −64 897 | −82 246 | −70 680 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −4 651 | −41 798 | −64 897 | −82 246 | −70 680 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 101 498 | 87 665 | 396 680 | 329 531 | 253 173 |
| Equity | 97 787 | 76 524 | 387 207 | 305 559 | 235 663 |
| Long-term debt | 0 | 0 | 0 | 103 | 427 |
| Short-term debt | 3 712 | 11 141 | 9 473 | 23 869 | 17 083 |
| Total debt | 3 712 | 11 141 | 9 473 | 23 972 | 17 510 |
EBITDA margin
-2554.3%
This company
15.8%
Market median
-16266% vs market
20202024
Equity ratio
93.1%
This company
38.2%
Market median
+144% vs market
20202024
Return on equity
-30.0%
This company
18.4%
Market median
-263% vs market
20202024
Net profit margin
-2381.4%
This company
8.1%
Market median
-29500% vs market
20202024
Asset turnover
0.01×
This company
1.12×
Market median
-99% vs market
20202024
Debt / equity
0.07×
This company
0.62×
Market median
+89% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-04-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
JM Chief Executive Officer | Chief Executive Officer | 2021 |
JE Chief Auditor | Chief Auditor | 2021 |
| Former (2) | ||
KD Chief Executive Officer | Chief Executive Officer | 2022 – 2024 |
DO Chief Executive Officer | Chief Executive Officer | 2024 – 2026 |
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
| Board of Directors | 2022 | |
| Chairman | 2026 | |
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Board of Directors | 2021 | |
| Former (4) | ||
| Deputy Board Member | 2020 – 2021 | |
| Deputy Board Member | 2020 – 2021 | |
| Board of Directors | 2020 – 2021 | |
| Board of Directors | 2022 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
A3P Biomedical AB (publ) 
A3P Lab ABBoard members of A3P Biomedical AB (publ) also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Karl David Rosén | Chief Executive Officer | 0 companies |
| Jan Martin Steinberg | Chief Executive Officer | 0 companies |
| Johan Erik Niclas Bergenmo | Chief Auditor | 0 companies |
| Daniel Ola Steinberg | Chief Executive Officer | 0 companies |
| Jeroen Tas | Board of Directors | 0 companies |
| Hans Jarl Rutger Arnhult | Deputy Board Member | 0 companies |
| Bo Daniel Falk | Deputy Board Member | 0 companies |
| Christopher James O'Connell | Chairman | 0 companies |
| Lars Anders Larsson | Board of Directors | 0 companies |
| Nils Thomas von Koch | Board of Directors | 0 companies |
| Marie Cecilia Edström | Board of Directors | 0 companies |
| Mark Royston Quick | Board of Directors | 0 companies |
| Per Henrik Grönberg | Board of Directors | 0 companies |